These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 21971829)

  • 1. Liver cancer targeting of Doxorubicin with reduced distribution to the heart using hematoporphyrin-modified albumin nanoparticles in rats.
    Chang JE; Shim WS; Yang SG; Kwak EY; Chong S; Kim DD; Chung SJ; Shim CK
    Pharm Res; 2012 Mar; 29(3):795-805. PubMed ID: 21971829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticancer efficacy of photodynamic therapy with hematoporphyrin-modified, doxorubicin-loaded nanoparticles in liver cancer.
    Chang JE; Yoon IS; Sun PL; Yi E; Jheon S; Shim CK
    J Photochem Photobiol B; 2014 Nov; 140():49-56. PubMed ID: 25090224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional alginate nanoparticles for efficient intracellular release of doxorubicin and hepatoma carcinoma cell targeting therapy.
    Guo H; Lai Q; Wang W; Wu Y; Zhang C; Liu Y; Yuan Z
    Int J Pharm; 2013 Jul; 451(1-2):1-11. PubMed ID: 23618965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asialoglycoprotein receptor targeted delivery of doxorubicin nanoparticles for hepatocellular carcinoma.
    Pranatharthiharan S; Patel MD; Malshe VC; Pujari V; Gorakshakar A; Madkaikar M; Ghosh K; Devarajan PV
    Drug Deliv; 2017 Nov; 24(1):20-29. PubMed ID: 28155331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Doxorubicin-loaded glycyrrhetinic acid modified recombinant human serum albumin nanoparticles for targeting liver tumor chemotherapy.
    Qi WW; Yu HY; Guo H; Lou J; Wang ZM; Liu P; Sapin-Minet A; Maincent P; Hong XC; Hu XM; Xiao YL
    Mol Pharm; 2015 Mar; 12(3):675-83. PubMed ID: 25584860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-density lipoprotein-coupled N-succinyl chitosan nanoparticles co-delivering siRNA and doxorubicin for hepatocyte-targeted therapy.
    Zhu QL; Zhou Y; Guan M; Zhou XF; Yang SD; Liu Y; Chen WL; Zhang CG; Yuan ZQ; Liu C; Zhu AJ; Zhang XN
    Biomaterials; 2014 Jul; 35(22):5965-76. PubMed ID: 24768047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel self-assembly albumin nanocarrier for reducing doxorubicin-mediated cardiotoxicity.
    Yuan A; Wu J; Song C; Tang X; Qiao Q; Zhao L; Gong G; Hu Y
    J Pharm Sci; 2013 May; 102(5):1626-35. PubMed ID: 23423631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiR-375 delivered by lipid-coated doxorubicin-calcium carbonate nanoparticles overcomes chemoresistance in hepatocellular carcinoma.
    Zhao P; Wu S; Cheng Y; You J; Chen Y; Li M; He C; Zhang X; Yang T; Lu Y; Lee RJ; He X; Xiang G
    Nanomedicine; 2017 Nov; 13(8):2507-2516. PubMed ID: 28577837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR Targeted Cetuximab-Valine-Citrulline (vc)-Doxorubicin Immunoconjugates- Loaded Bovine Serum Albumin (BSA) Nanoparticles for Colorectal Tumor Therapy.
    Ye Z; Zhang Y; Liu Y; Liu Y; Tu J; Shen Y
    Int J Nanomedicine; 2021; 16():2443-2459. PubMed ID: 33814909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo pharmacokinetics, biodistribution and the anti-tumor effect of cyclic RGD-modified doxorubicin-loaded polymers in tumor-bearing mice.
    Wang C; Li Y; Chen B; Zou M
    Colloids Surf B Biointerfaces; 2016 Oct; 146():31-8. PubMed ID: 27244048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of co-treatment with doxorubicin and verapamil loaded into chitosan nanoparticles on diethylnitrosamine-induced hepatocellular carcinoma in mice.
    Abo Mansour HE; El-Batsh MM; Badawy NS; Mehanna ET; Mesbah NM; Abo-Elmatty DM
    Hum Exp Toxicol; 2020 Nov; 39(11):1528-1544. PubMed ID: 32519553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatocellular carcinoma dually-targeted nanoparticles for reduction triggered intracellular delivery of doxorubicin.
    Mezghrani O; Tang Y; Ke X; Chen Y; Hu D; Tu J; Zhao L; Bourkaib N
    Int J Pharm; 2015 Jan; 478(2):553-68. PubMed ID: 25455765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biotin-Conjugated Multilayer Poly [D,L-lactide-co-glycolide]-Lecithin-Polyethylene Glycol Nanoparticles for Targeted Delivery of Doxorubicin.
    Dai Y; Xing H; Song F; Yang Y; Qiu Z; Lu X; Liu Q; Ren S; Chen X; Li N
    J Pharm Sci; 2016 Sep; 105(9):2949-2958. PubMed ID: 27209461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A galactosamine-mediated drug delivery carrier for targeted liver cancer therapy.
    Shen Z; Wei W; Tanaka H; Kohama K; Ma G; Dobashi T; Maki Y; Wang H; Bi J; Dai S
    Pharmacol Res; 2011 Oct; 64(4):410-9. PubMed ID: 21723392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Doxorubicin and paclitaxel co-bound lactosylated albumin nanoparticles having targetability to hepatocellular carcinoma.
    Thao LQ; Lee C; Kim B; Lee S; Kim TH; Kim JO; Lee ES; Oh KT; Choi HG; Yoo SD; Youn YS
    Colloids Surf B Biointerfaces; 2017 Apr; 152():183-191. PubMed ID: 28110040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Folate-receptor mediated pH/reduction-responsive biomimetic nanoparticles for dually activated multi-stage anticancer drug delivery.
    Wang D; Chen W; Li H; Huang G; Zhou Y; Wang Y; Wan W; You B; Liu Y; Zhang X
    Int J Pharm; 2020 Jul; 585():119456. PubMed ID: 32492507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Codelivery of doxorubicin and elacridar to target both liver cancer cells and stem cells by polylactide-co-glycolide/d-alpha-tocopherol polyethylene glycol 1000 succinate nanoparticles.
    Chen D; Pan X; Xie F; Lu Y; Zou H; Yin C; Zhang Y; Gao J
    Int J Nanomedicine; 2018; 13():6855-6870. PubMed ID: 30498347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
    Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
    Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyaluronic acid derivative-based self-assembled nanoparticles for the treatment of melanoma.
    Jin YJ; Termsarasab U; Ko SH; Shim JS; Chong S; Chung SJ; Shim CK; Cho HJ; Kim DD
    Pharm Res; 2012 Dec; 29(12):3443-54. PubMed ID: 22886625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lactoferrin-modified poly(ethylene glycol)-grafted BSA nanoparticles as a dual-targeting carrier for treating brain gliomas.
    Su Z; Xing L; Chen Y; Xu Y; Yang F; Zhang C; Ping Q; Xiao Y
    Mol Pharm; 2014 Jun; 11(6):1823-34. PubMed ID: 24779677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.